TWI676618B - 三環化合物 - Google Patents

三環化合物 Download PDF

Info

Publication number
TWI676618B
TWI676618B TW104134975A TW104134975A TWI676618B TW I676618 B TWI676618 B TW I676618B TW 104134975 A TW104134975 A TW 104134975A TW 104134975 A TW104134975 A TW 104134975A TW I676618 B TWI676618 B TW I676618B
Authority
TW
Taiwan
Prior art keywords
carbazole
carboxamide
fluoro
tetrahydro
methyl
Prior art date
Application number
TW104134975A
Other languages
English (en)
Chinese (zh)
Other versions
TW201629014A (zh
Inventor
賽林 阿曼德
Saleem Ahmad
道格拉斯Ｇ 巴特
Douglas G. Batt
慶杰 劉
Qingjie Liu
約翰Ｅ 馬可
John E. Macor
約瑟夫Ａ 提諾
Joseph A. Tino
史考特 杭特 瓦特森
Scott Hunter Watterson
沙堤西 可薩文 奈爾
Satheesh Kesavan NAIR
塔朗 庫瑪 梅修
Tarun Kumar MAISHAL
Original Assignee
美商必治妥美雅史谷比公司
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54427879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI676618(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 美商必治妥美雅史谷比公司, Bristol-Myers Squibb Company filed Critical 美商必治妥美雅史谷比公司
Publication of TW201629014A publication Critical patent/TW201629014A/zh
Application granted granted Critical
Publication of TWI676618B publication Critical patent/TWI676618B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
TW104134975A 2014-10-24 2015-10-23 三環化合物 TWI676618B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462068234P 2014-10-24 2014-10-24
US62/068,234 2014-10-24

Publications (2)

Publication Number Publication Date
TW201629014A TW201629014A (zh) 2016-08-16
TWI676618B true TWI676618B (zh) 2019-11-11

Family

ID=54427879

Family Applications (1)

Application Number Title Priority Date Filing Date
TW104134975A TWI676618B (zh) 2014-10-24 2015-10-23 三環化合物

Country Status (34)

Country Link
US (3) US10266491B2 (cg-RX-API-DMAC7.html)
EP (1) EP3209651B9 (cg-RX-API-DMAC7.html)
JP (1) JP6599983B2 (cg-RX-API-DMAC7.html)
KR (1) KR102514914B1 (cg-RX-API-DMAC7.html)
CN (1) CN107074804B (cg-RX-API-DMAC7.html)
AR (1) AR102427A1 (cg-RX-API-DMAC7.html)
AU (1) AU2015335703B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017007545A2 (cg-RX-API-DMAC7.html)
CA (1) CA2965523A1 (cg-RX-API-DMAC7.html)
CL (1) CL2017001001A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017004517A2 (cg-RX-API-DMAC7.html)
CY (1) CY1122549T1 (cg-RX-API-DMAC7.html)
DK (1) DK3209651T3 (cg-RX-API-DMAC7.html)
EA (1) EA032361B1 (cg-RX-API-DMAC7.html)
ES (1) ES2761903T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20192197T2 (cg-RX-API-DMAC7.html)
HU (1) HUE048321T2 (cg-RX-API-DMAC7.html)
IL (1) IL251798B (cg-RX-API-DMAC7.html)
LT (1) LT3209651T (cg-RX-API-DMAC7.html)
MA (1) MA40302B1 (cg-RX-API-DMAC7.html)
ME (1) ME03754B (cg-RX-API-DMAC7.html)
MX (1) MX374724B (cg-RX-API-DMAC7.html)
MY (1) MY190568A (cg-RX-API-DMAC7.html)
PE (1) PE20171239A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017500724B1 (cg-RX-API-DMAC7.html)
PL (1) PL3209651T3 (cg-RX-API-DMAC7.html)
PT (1) PT3209651T (cg-RX-API-DMAC7.html)
RS (1) RS59707B1 (cg-RX-API-DMAC7.html)
SG (2) SG10201903619YA (cg-RX-API-DMAC7.html)
SI (1) SI3209651T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202000035T1 (cg-RX-API-DMAC7.html)
TN (1) TN2017000158A1 (cg-RX-API-DMAC7.html)
TW (1) TWI676618B (cg-RX-API-DMAC7.html)
WO (1) WO2016065236A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53568A (fr) 2014-10-24 2022-02-23 Takeda Pharmaceuticals Co Médicaments pour le traitement de maladies ophtalmiques
ES2800173T3 (es) * 2014-10-24 2020-12-28 Bristol Myers Squibb Co Compuestos de atropisómeros tricíclicos
KR102327917B1 (ko) * 2016-07-07 2021-11-17 주식회사 대웅제약 신규한 4-아미노피라졸로[3,4-d]피리미디닐아자바이사이클로 유도체 및 이를 포함하는 약학 조성물
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
WO2019075386A1 (en) 2017-10-13 2019-04-18 The Regents Of The University Of California MODULATORS OF MTORC1
CN109053542A (zh) * 2018-07-25 2018-12-21 南通大学 一种6-溴-5-羟基异吲哚啉-1-酮的化学合成方法
EP4038059B1 (en) * 2019-10-04 2023-09-20 Bristol-Myers Squibb Company Substituted carbazole compounds
CN110862396B (zh) * 2019-11-29 2021-06-04 浙江工业大学 一种吡咯并[3,4-c]咔唑-1,3(2H，6H)-二酮类化合物的合成方法
US20220009920A1 (en) * 2020-04-10 2022-01-13 Gb005, Inc. Kinase inhibitors
US12448363B2 (en) 2020-06-02 2025-10-21 Vidya Therapeutics, Inc. Kinase inhibitors
CN115232061B (zh) * 2021-09-18 2024-01-30 山西紫罗蓝新材料科技有限公司 一种3-硝基-9-乙基咔唑粗产物的提取工艺
KR20250034121A (ko) * 2022-07-06 2025-03-10 비비디온 테라퓨틱스, 인코포레이티드 Wrn 헬리케이스 억제제를 포함하는 약제학적 조성물
CA3268880A1 (en) * 2022-09-29 2024-04-04 Vividion Therapeutics, Inc. N-ACRYLOYLMORPHOLINE DERIVATIVES USED AS KEAP1 MODULATORS AND RELATED USES

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100160303A1 (en) * 2008-12-19 2010-06-24 Bristol-Myers Squibb Company Carbazole carboxamide compounds useful as kinase inhibitors

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
CA2140722A1 (en) 1994-01-24 1995-07-25 Joseph A. Jakubowski Beta-carboline thromboxane synthase inhibitors
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
WO2005005429A1 (en) 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
WO2005047290A2 (en) 2003-11-11 2005-05-26 Cellular Genomics Inc. Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors
WO2006044687A2 (en) 2004-10-15 2006-04-27 Takeda San Diego, Inc. Kinase inhibitors
KR20070119606A (ko) 2004-11-10 2007-12-20 씨지아이 파마슈티칼스, 인크. 특정 이미다조[１,２-ａ]피라진-８-일아민, 그의 제조 방법및 용도
AU2005315319B2 (en) 2004-12-17 2011-07-07 Glenmark Pharmaceuticals S.A. Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US8518964B2 (en) * 2005-11-22 2013-08-27 Merck Sharp & Dohme Corp. Tricyclic compounds useful as inhibitors of kinases
CA2663178C (en) 2006-09-11 2016-01-12 Matrix Laboratories Ltd. Dibenzofuran derivatives as inhibitors of pde-4 and pde-10
US20100160292A1 (en) 2006-09-11 2010-06-24 Cgi Pharmaceuticals, Inc Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors
US20090062251A1 (en) 2007-08-17 2009-03-05 Astrazeneca Ab Novel Compounds 002
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
CA2707491A1 (en) 2007-12-13 2009-06-18 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
PT2247558T (pt) 2008-02-14 2022-03-21 Lilly Co Eli Novos agentes de imagiologia para deteção de disfunção neurológica
GB0809360D0 (en) 2008-05-22 2008-07-02 Isis Innovation Calcium modulation
EP2307377A1 (en) 2008-06-18 2011-04-13 Pfizer Limited Nicotinamide derivatives
CA2986640C (en) 2008-06-27 2019-03-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
EP2151441A1 (en) 2008-08-06 2010-02-10 Julius-Maximilians-Universität Würzburg Beta-carbolin-derivates as substrates for an enzyme
CN101475571B (zh) 2009-01-21 2011-06-22 中国药科大学 β-咔啉类细胞周期蛋白依赖性激酶2抑制剂及其用途
ES2733093T3 (es) 2009-02-13 2019-11-27 Nextivity Inc Control remoto para amplificador
EP2582668B1 (en) 2010-06-16 2016-01-13 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
EP2455378A1 (en) 2010-11-03 2012-05-23 Philip Morris Products S.A. Carbazole and carboline derivatives, and preparation and therapeutic applications thereof
AU2011330850B2 (en) 2010-11-15 2016-01-28 Viiv Healthcare Uk Limited Inhibitors of HIV replication
PH12013502379A1 (en) 2011-05-17 2014-01-13 Hoffmann La Roche Inhibitors of bruton's tyrosine kinase
HK1209632A1 (en) 2012-01-10 2016-04-08 林伯士艾瑞斯公司 Irak inhibitors and uses thereof
KR20150060839A (ko) 2012-10-26 2015-06-03 에프. 호프만-라 로슈 아게 브루톤 티로신 키나아제의 억제제
UY35625A (es) * 2013-06-25 2014-12-31 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos como inhibidores de quinasa
EP3013815B1 (en) * 2013-06-25 2017-05-03 Bristol-Myers Squibb Company Carbazole carboxamide compounds useful as kinase inhibitors
HUE050706T2 (hu) 2014-10-24 2020-12-28 Bristol Myers Squibb Co Indol karboxamid vegyületek, amelyek hasznosak kináz inhibitorokként
ES2800173T3 (es) * 2014-10-24 2020-12-28 Bristol Myers Squibb Co Compuestos de atropisómeros tricíclicos

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100160303A1 (en) * 2008-12-19 2010-06-24 Bristol-Myers Squibb Company Carbazole carboxamide compounds useful as kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
George A. Patani et al."Bioisosterism: A Rational Approach in Drug Design." Chemical Reviews.1996,96,3147-3176. *

Also Published As

Publication number Publication date
KR102514914B1 (ko) 2023-03-27
CA2965523A1 (en) 2016-04-28
JP6599983B2 (ja) 2019-10-30
AU2015335703A1 (en) 2017-06-08
CO2017004517A2 (es) 2017-08-31
PE20171239A1 (es) 2017-08-24
US10266491B2 (en) 2019-04-23
CN107074804A (zh) 2017-08-18
IL251798B (en) 2020-08-31
HUE048321T2 (hu) 2020-07-28
EP3209651B9 (en) 2020-05-20
SG11201703187PA (en) 2017-05-30
KR20170075756A (ko) 2017-07-03
EP3209651B1 (en) 2019-10-23
AR102427A1 (es) 2017-03-01
PH12017500724A1 (en) 2017-10-09
MY190568A (en) 2022-04-27
AU2015335703B2 (en) 2020-05-21
ES2761903T3 (es) 2020-05-21
US20200255377A1 (en) 2020-08-13
PH12017500724B1 (en) 2023-07-05
EA032361B1 (ru) 2019-05-31
US10676434B2 (en) 2020-06-09
SG10201903619YA (en) 2019-05-30
TW201629014A (zh) 2016-08-16
MA40302A1 (fr) 2018-05-31
RS59707B1 (sr) 2020-01-31
CY1122549T1 (el) 2021-01-27
HRP20192197T1 (hr) 2020-03-06
EP3209651A1 (en) 2017-08-30
HRP20192197T8 (hr) 2020-04-03
MX374724B (es) 2025-03-06
WO2016065236A1 (en) 2016-04-28
HRP20192197T2 (hr) 2020-11-13
MA40302B1 (fr) 2018-10-31
SI3209651T1 (sl) 2019-12-31
DK3209651T3 (da) 2020-02-03
US20190225583A1 (en) 2019-07-25
LT3209651T (lt) 2020-01-10
CN107074804B (zh) 2020-02-18
CL2017001001A1 (es) 2017-11-24
TN2017000158A1 (en) 2018-10-19
BR112017007545A2 (pt) 2017-12-19
PT3209651T (pt) 2019-12-30
ME03754B (me) 2021-04-20
JP2017535536A (ja) 2017-11-30
IL251798A0 (en) 2017-06-29
MX2017005255A (es) 2017-08-18
US11053197B2 (en) 2021-07-06
EA201790745A1 (ru) 2017-08-31
US20170362176A1 (en) 2017-12-21
SMT202000035T1 (it) 2020-03-13
PL3209651T3 (pl) 2020-03-31

Similar Documents

Publication Publication Date Title
TWI676618B (zh) 三環化合物
TWI744218B (zh) 吲哚甲醯胺化合物
TWI851557B (zh) 藥學化合物
CN107873031B (zh) 作为tnf活性调节剂的苯并噁嗪酮衍生物及其类似物
CN110582495B (zh) 作为tnf活性的调节剂的稠合五环咪唑衍生物
TW201722933A (zh) 苯內醯胺化合物
TW201718536A (zh) 可作為ＴＮＦα調節劑之雜環化合物
CN105530932A (zh) 作为bik抑制剂的伯甲酰胺
CN105683188A (zh) 作为fgfr4抑制剂的稠环二环吡啶基衍生物
JP7545467B2 (ja) 置換カルバゾール化合物
CN107108555B (zh) 三环阻转异构体化合物
KR20160022890A (ko) 키나제 억제제로서 유용한 카르바졸 카르복스아미드 화합물
CN115867346A (zh) 激酶抑制剂
CN116600808A (zh) 一类作为kras突变体g12c抑制剂的四氢萘啶类衍生物、其制备方法及其应用
JP2025536323A (ja) 縮合二環式化合物ならびにＭｅｒ阻害剤およびＡｘｌ阻害剤としてのその使用
HK1238642B (en) Carbazole derivatives
HK1238642A1 (en) Carbazole derivatives

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees